https://www.selleckchem.com/pr....oducts/valproic-acid
AIMS To comprehensively evaluate the safety of dapagliflozin in patients with type 2 diabetes (T2DM) with emphasis placed on potential safety concerns related to the SGLT2-inhibitors class. METHODS In DECLARE-TIMI 58, 17,160 patients with T2DM were randomized to dapagliflozin or placebo and followed for a median of 4.2 years. Safety was evaluated in 17,143 patients receiving at least one dose of study drug. RESULTS Acute kidney injury occurred less frequently with dapagliflozin, and adverse events suggestive of volume depletion we
כמו
תגובה
לַחֲלוֹק
